Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2026.

LIJENBU RKT Jenburkt Pharmaceuticals Limited Regd. Office : UNICORN, 14th Floor, Daittaji Salvi Marg, Off Veera De sai Road, Andheri West, Mumbai 400 053. Phone: 022-67 603 603 Ref. No. JPL/CS/2371/2026 Date: 3 November, 2026. BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Script Code : 524731 Sub.: Outcome of Board Meeting held today, i.e. 3" November, 2026 —Standalone Unaudited Financial Results for the quarter and half year ended on 30 September, 2026. Reg.: Regulation 30(2) and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Dear Sir, 1. The Standalone Unaudited Financial Statements for the quarter and half year ended on 30" September, 2026 have been approved and adopted by the Board, on the recommendation of Audit Committee, vide their meeting held on even date. The same has been attached herewith in the format required under Regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, along with statement of standalone Assets & Liabilities as ‘at 30"" September, 2026 and Cash Flow statement for the half year ended on 30" September, 2026, as annexure A and B respectively. 2. The Limited Audit Review Report dated 3" November, 2026, of Auditors of the Company, on the standalone unaudited financial results for the quarter ended on 30" September, 2026, is also attached. The Board Meeting commenced at 2.30 p.m. and was concluded at 05.20 p.m. Kindly take on record the above and acknowledge. Thanking you, oS a & Encl.: As Stated Above. *K & #8 Science hai toh Hope hai ¥% Hope hai toh Health hai %# Health hai toh Happiness hai oC Email: info@jenburkt.cam www jenburkt.c om CIN No, L24230MH1985PL.C036541 oe LAJENBU RKT Jenburkt Pharmaceuticals Limited UNICORN, 14th Floor, Dattaji Salvi Marg, Off Veera Desai Road, Andheri West, Mumbai 400 053. Phone: 022-67 603 603 Statement of Standalone Unaudited Financial Results for the Quarter & Half Year Ended on 30th September, 2026 (%. in Lacs other than EPS) Particulars Quarter Ended Year to Date Year Ended 30-09-2026 ] 30-06-2026] 30-09-2025 30-09-2026] 30-09-2025] 31-03-2026 Unaudited ] Unaudited| Unaudited] Unaudited| Unaudited Audited 1|Revenue from Operations 4831.8 2 3551.20 4555.76 8383.02 8108.44 16874.06 11} Other Income 225.2 6 151.32 207.90 376.58 413.61 1029.94 Ill] Total income (I + II) 5057.0 8 3702.52 4763.66 8759.60 8522.05 17904.00 IV} Expenses (a)| Cost of Materials Consumed 195.6 5 231.59 219.35 427.24 432.89 899.35 (b)| Purchase of Stock-in-trade 719.9 6 547.84 628.33] 1267.80 1165.57 2817.89 (c) Changes in inventories of Finished Goods, Stock-in- trade and WIP 79.01 -147.24 -12.04 -68.23 -111.06 -484.67 (d)|Employee benefit expenses 1487.4 4 1302.52 1393.25 2789.96 2565.33 4988.22 (e)| Finance Costs 12.9 7 13.02 10.74 25.99 21.73 46.20 (f )| Depreciation and Amortisation Expense 79.8 9 64.07 74.39 143.96 146.64 310.76 (g)| Other expenses 1048.2 1 1013.81 1016.44 2062.02 1849.55 4279.25 Total Expenses (IV) 3623.1 3 3025.61 3330.46 6648.74 6070.65 12857.00 V| Profit before exceptional items and tax (III-IV) 1433.9 5 676.91 1433.20 2110.86 2451.40 5047.00 VI} Exceptional items Impact of Labour Codes # 0. 00 0.00 0.00 0.00 0.00 395.11 Vil| Profit before tax (V-VI) 1433.9 5 676.91 1433.20 2110.86 2451.40 4651.89 Vill] Tax Expense (i)| Current Tax 350.0 0 100.00 400.00 450.00 600.00 1260.00 (ii)| Income Tax for previous years 0. 00 0.00 0.00 0.00 0.00 4.10 (iii)| Deferred Tax 63.0 1 -11.65 16.86 51.36 55.88 -85.81 IX|Profit/(Loss) after Tax (VII-VII) 1020.9 4 588.56 1016.34 1609.50 1795.52 3473.60 X| Other Comprehensive Income A|(i) Items that will not be reclassified to profit or loss -64. 20 163.76 -45.10 99.56 110.09 -171.20 (ii) Income Tax relatiing to Items that will not be reclassified to profit or loss 7.34 -13.51 16.97 -6.17 -0.79 18.30 B|(i) Items that will be reclassified to profit or loss 0. 00 0.00 0.00 0.00 0.00 0.00 (ii) Income Tax relatiing to Items that will be reclassified to profit or loss 0.00 0.00 0.00 0.00 0.00 0.00 XI/Total Comprehensive Income for the period (IX+X) 964.0 8 738.81 988.21 1702.89 1904.82 3320.70 Paid up Equity Share Capital (F.V. Rs.10/- each) 441,3 3 441.33 441.33 441,33 441.33 441.33 ef Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted 23.13 13.34 23.03 36.47 40.68 78.71 Notes: 1 The above statement of standalone unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 3rd November, 2026. 2 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable. 3 The Statement of Assets and Liablilites as at 30th Septemeber 2026 and Cashflow Statement for the half year ended 30th Septemeber 2026 are annexed as Annexure A & B respectively. 4 # The Government of India notified the Revised Labour Codes on November 21, 2025, resulting in an increase of 3395.11 lakhs in gratuity and leave liabilities due to past service costs arising from plan amendments in FY 2025-26. For Jenburkt Pharmaceuticals Limited LLA Le 1X. & 78 Place : Mumbai (Ashish U. on ge Date : 3rd November, 2026 Chairman & Managing Directo fm, (DIN No: 00226479) 44 Science hai toh Hope hai 4% Hope hai toh Health hai 4% e h hai toh Happiness hai 3 = Email: info@jenburkt.com www.jenburkt.com CIN No. L24230MH1985PLC036541 se [1JENBURKT Annexure -A Statement of Standalone Assets & Liabilities < in Lacs Particulars 30/09/2026 31/03/2026 Amount Amount ASSETS (1) Non-current Assets (a) Property, Plants & Equipments 6564.34 1130.41 (b) Right to Use Asset 760.57 791.63 (c) Other Intangible assets 27.98 24,14 (d) Capital Work In Progress 328.27 4611.93 (e) Financial Assets (i) |Investments 1939.58 2702.37 (ii) [Loans 0.10 0.70 (iil) | Other Financial Assets 1439,43 3466.07 Deferred Tax Asset 250.45 239.90 (f) Other Non-current Assets 85.89 125,16 (2) Current assets (a) Inventories 1509.74 1363.31 (b) Financial Assets (i) |Investments 1062.04 0.00 (ii) |Trade Receivables 1982.56 2435.69 (iii) | Cash and Cash Equivalents 602.60 557.71 (iv) |Bank Balance other than (iii) 6486.48 4753.74 (v) |Loans 33.31 6.34 (vi) | Other Financial Assets 66.48 39.80 (c) Other Current Assets 272.97 336.53 Current Tax Asset (Net) 78.77 15.81 Total Assets 23,491.58 22,601.26 EQUITY AND LIABILITIES (1) Equity (a) Equity Share Capital 441,33 441.33 (b) Other Equity - Reserves & Surplus 20,052.02 19,262.69 Liabilities (2) Non-current liabilities (a) Financial Liabilities (i) [Lease Liabilities 154.63 183.95 (ii) Other Financial Liabilities 301.03 301.03 (b) Deferred Tax Liability 165.68 97.59 (3) Current Liabilities (a) Financial Liabilities (i) |Lease Liabilities 70.59 64.87 (ii) |Trade Payables (A) Total Gui nding dues of Micro Enterprises an d Small 5763 57.48 Enterprises; and (B) Total Cunstandiag dues of Ceealiors other than Micro 753.01 955.89 Enterprises and Small Enterprises. (iv) | Other Financial Liabilities 441.78 539.83 (b) Other Current Liabilities 334.40 126.96 (c) Provisions # 748.97 659.26 (a) Current Tax Liabilities (Net) - 113.80 Total Equity and Liabilities 23,491.58 22,601.26 Note # The Government of India notified the Revised Labour Codes on November 21, 2025, resulting in an increase of 3395.11 lakhs in gratuity and leave liabilities due to past service costs arising from plan amendments in FY 2025-26. By order of the Board For Jenburkt Pharmaceuticals Limited Place : Mumbai (ASHISH U BHUTA) Date : 3rd November, 2626 CHAIRMAN AND MANAGING DIRECTOR (DIN No: 00226479) [a\JENBURKT Annexure - B Cashflow Statement for the year ended 30th September, 2026 Rs in Lacs 30-09-2026 31-03-2026 A. CASH FLOW FROM OPERATING ACTIVITIES : a Net Profit After Tax 1,609.50 3,473.60 Adjustments for : i |Depreciation and Amortisation Expense 143.96 310.77 ii |Loss on Fixed Assets scrapped (1.03) 4.52 iii |}Tax Expense 501.36 1,178.29 iv |Finance Cost 25.99 46.20 v |Interest Income (291.78) ( [Showing first 8,000 characters — download PDF for full document]